Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel treatment for mantle cell lymphoma - impact of BTK inhibitors and beyond.

Leukemia & lymphoma - 1 Jan 2024

Gribbin Caitlin, Chen Jane, Martin Peter, Ruan Jia

Abstract excerpt

Mantle cell lymphoma (MCL) primarily affects older adults, accounting for 3-10% of all non-Hodgkin lymphoma (NHL) in western countries. The disease course of MCL is heterogenous; driven by clinical, cytogenetics, and molecular features that shape differences in outcomes, including proliferation index, MIPI scores, and mutational profile such as TP53 aberration. The advent of novel agents has fundamentally evolved...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to BTK gene
Share to TP53 gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lymphoma, Mantle-Cell

Share to Mutation

Source

Identifiers

PMID: 37800170
DOI: 10.1080/10428194.2023.2264430

Genes

BTK
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel treatment for mantle cell lymphoma - impact of BTK inhibitors and beyond.PMID 37800170Read ↗

Mantle cell lymphoma: evolving management strategies.Semantic proximity Read ↗

Exploiting gene mutations and biomarkers to guide treatment recommendations in mantle cell lymphoma.Semantic proximity Read ↗

BTK Inhibitors and BTK Degraders for the Treatment of Mantle Cell Lymphoma - Current Status and PerspectivesSemantic proximity Read ↗

Novel agents for mantle cell lymphoma: molecular rational and clinical data.Semantic proximity Read ↗

Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agentsSemantic proximity Read ↗

Your chemo is no good here: management of high-risk MCL.Semantic proximity Read ↗

Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic eraSemantic proximity Read ↗

Diffuse large B cell lymphoma: molecular targeted therapy.Semantic proximity Read ↗

Unraveling MCL biology to understand resistance and identify vulnerabilitiesSemantic proximity Read ↗

Dual targeting of BTK and BCL2 enhances apoptosis in marginal zone lymphoma models: preclinical activity of BGB-16673 and sonrotoclaxSemantic proximity Read ↗

[Mantle cell lymphoma: Towards a personalized therapeutic strategy?].Semantic proximity Read ↗

Precision therapy for lymphoma--current state and future directions.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.